How to Write a Hormone Therapy Informed Consent That Protects You

An informed consent document is not a liability shield you hand a patient to sign; it is the written record of a conversation that already happened. Done well, it protects the patient by making risks concrete, and it protects the practice by proving the conversation took place. Done badly — a generic template copied from another clinic — it proves the opposite. This is the structure the operating team uses for hormone therapy consents across our clinics, with the language choices that matter.

Principles before sections

• One consent per therapy class. Testosterone therapy, female hormone therapy, thyroid, peptides and GLP-1s each get their own document. A single catch-all consent is harder to defend because it cannot be specific.
• Plain language at roughly an eighth-grade reading level. Short sentences, defined terms, no abbreviations without the full phrase first.
• Specific, not exhaustive. List the material risks a reasonable patient would want to know, not every event ever reported. Your state’s standard for disclosure varies — confirm with counsel.
• The consent mirrors the note. The visit note should state that risks, benefits and alternatives were discussed and that the patient’s questions were answered. The document and the note corroborate each other.

The sections, in order

1. Identification and purpose

Patient name, date of birth, clinic legal name, prescriber name and credential, and a one-sentence purpose: “This document explains the proposed treatment, its risks and benefits, and the alternatives, so you can decide whether to proceed.”

2. Diagnosis and proposed treatment

State the clinical basis in the patient’s own terms (“symptoms consistent with low testosterone confirmed by two morning blood tests”) and the proposed therapy, route and starting regimen. Reference the treatment plan in the chart for specifics so the consent does not have to be re-signed with every dose change.

3. Expected benefits, stated carefully

Use “may” and “many patients report.” Never promise outcomes. “Many patients report improved energy, mood, libido and body composition over several months; individual results vary and some patients do not experience these benefits.”

4. Material risks and side effects

For testosterone, include at minimum: suppression of natural testosterone production and sperm production (possible infertility, which may not fully reverse), increased red blood cell count requiring monitoring, acne and oily skin, fluid retention, breast tenderness or enlargement, mood changes, worsening of sleep apnea, prostate effects requiring monitoring, injection-site reactions, and the uncertainty regarding cardiovascular risk in the current literature. For estradiol and progesterone, include breast tenderness, bleeding changes, clot risk (route-dependent), gallbladder effects, and the age- and timing-dependent findings on breast cancer and cardiovascular risk. Keep this list current with guideline updates and have your collaborating physician or medical director review it annually.

5. Off-label and compounded-product disclosure

This section is where most templates fail. Say exactly what is and is not approved:

• “Testosterone products are FDA-approved for men with certain medical conditions causing low testosterone. Use for other purposes, or in women, is considered off-label. Off-label prescribing is legal and common, but the FDA has not evaluated safety or effectiveness for that use.”
• “Compounded medications are prepared by a licensed pharmacy for an individual patient. They are not FDA-approved and have not been reviewed by the FDA for safety, effectiveness or quality.”
• For peptides and other investigational or unapproved products, state plainly that they are not FDA-approved for any use and describe the regulatory status accurately — which varies and changes; confirm with your pharmacy and counsel.

6. Alternatives

List the real options: no treatment, lifestyle intervention, different routes (injection versus gel versus pellet), fertility-preserving alternatives where relevant, and referral to a specialist. A consent that lists no alternatives suggests none were discussed.

7. Patient responsibilities and monitoring

State the required follow-up labs and visits (for example, labs at 6–8 weeks and then every 6 months), the symptoms that require immediate contact, that the patient will not share or alter medication, and that failure to complete monitoring may result in treatment being paused. This section ties directly to your clinic operations workflow for follow-up scheduling.

8. Telehealth-specific consent

Confirm the patient understands care is delivered remotely, the limits of remote examination, the technology used, what happens if the connection fails, and that they must be physically located in a state where the prescriber is licensed at the time of each visit. Many states require specific telehealth consent language — varies by state; confirm with your board.

9. Controlled-substance agreement (testosterone)

Either a separate agreement or an embedded section: one prescriber, one pharmacy, no early refills, PDMP monitoring, safe storage, and conditions for discontinuation.

10. Financial consent

Cash-pay status, that the clinic does not bill insurance, that superbills may or may not be provided, the membership terms, and the refund and cancellation policy. Keep it short and consistent with the fee schedule on your website.

11. Acknowledgment and signatures

“I have read this document, I have had the opportunity to ask questions and they were answered, I understand I may withdraw consent at any time, and I consent to the treatment described.” Patient e-signature with date and time stamp, prescriber signature, and the consent version number in the footer. E-signature through your EHR or a HIPAA-covered e-sign tool is acceptable in most states; keep the audit trail.

Operational details that make it hold up

• Version-control the document. Change the version number and date whenever the text changes, and keep every prior version.
• Re-consent on material changes: a new therapy class, a switch to a compounded product, or a significant guideline change.
• Deliver it before the visit, discuss it during, sign after. A signature timestamped two minutes before a 20-minute visit raises questions.
• Store signed consents in the chart, not in an email inbox.

A consent that has been reviewed by your counsel and your malpractice carrier is worth the few hundred dollars it costs. The Institute’s telemedicine hormone clinic compliance guide lists it among the documents to have ready before the first patient.

FAQ

Can I use one consent for all hormone therapies?

You can, but it is weaker. Therapy-specific consents allow specific risk disclosures and off-label statements, which is what a reviewer or carrier wants to see. Most of our clinics use four to five separate documents.

Is an e-signature enough?

In most states, yes, when the e-sign tool records identity, timestamp and the exact document version. Keep the audit trail and confirm any state-specific requirements with counsel.

How often should the consent be updated?

Review it annually and whenever guidelines, products or your protocols change. Have the medical director or collaborating physician sign off on each revision so the clinical content is current.